



September 6, 2016

The Honorable Fred Upton
Chairman
U.S. House of Representatives
Energy and Commerce Committee
Washington, D.C. 20515

The Honorable Frank Pallone
Ranking Member
U.S. House of Representatives
Energy and Commerce Committee
Washington, D.C. 20515

The Honorable Joe Pitts
Chairman
U.S. House of Representatives
Health Subcommittee
Washington, D.C. 20515

The Honorable Gene Green
Ranking Member
U.S. House of Representatives
Health Subcommittee
Washington, D.C. 20515

The Honorable Pete Olson
U.S. House of Representatives
2133 Rayburn House Office Bldg.
Washington, D.C. 20515

The Honorable Dave Loebsack
U.S. House of Representatives
1527 Longworth House Office Bldg.
Washington, D.C. 20515

Dear Representatives Upton, Pallone, Pitts, Green, Olson and Loebsack:

The Diabetes Advocacy Alliance™ (DAA) would like to express our support and appreciation for the public health hearing the House Energy and Commerce Committee's Subcommittee on Health has scheduled for September 8th, 2016 regarding H.R. 1192, the "*National Diabetes Clinical Care Commission Act*." The DAA strongly supports this legislation and urges the Energy and Commerce Committee to pass the legislation as soon as possible so it can move expeditiously to the House and Senate floors for approval.

The DAA is a coalition of 21 diverse member organizations, representing patient, professional and trade associations, other non-profit organizations, and corporations, all united in the desire to change the way diabetes is viewed and treated in America. Since 2010, the DAA has worked to increase awareness of, and action on, the diabetes epidemic among legislators and policymakers. The organizations that comprise the DAA share a common goal of elevating diabetes on the national agenda so we may ultimately defeat diabetes.

The "*National Diabetes Clinical Care Commission Act*" creates a commission comprised of federal government leaders and private sector experts in diabetes and its disease complications to review how the government is currently spending resources on activities related to the diagnosis and treatment of diabetes and other metabolic, autoimmune and insulin resistant diseases. The commission would then make critically important recommendations on how to utilize these funds more effectively. The legislation has the potential to reduce the overwhelming impact diabetes has on health spending while at the same time improving care for some of the nearly 30 million Americans living with diabetes and the many more tens of millions of Americans

impacted by the disease.

Again, we thank you and the Members of the Energy and Commerce Committee for taking action to advance H.R. 1192 which has very strong, bipartisan support. The DAA looks forward to working with you to secure its passage by the House of Representatives and Senate this year.

Sincerely,

Karin Gillespie
Novo Nordisk
DAA Co-chair

Meghan Riley
American Diabetes Association
DAA Co-chair

Henry Rodriguez, MD
Pediatric Endocrine Society
DAA Co-chair